Advertisement

Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study

      Abstract

      Alanine aminotransferase (ALT) is a marker of non-alcoholic fatty liver disease (NAFLD) and predicts incident type 2 diabetes mellitus (DM2). Recently, ALT was shown to be also associated with endothelial dysfunction and carotid atherosclerosis. We studied the predictive value of ALT for all-cause mortality, incident cardiovascular disease (CVD) and coronary heart disease (CHD) events in a population-based cohort of Caucasian men and women aged 50–75 years, at baseline. The 10-year risk of all-cause mortality, fatal and non-fatal CVD and CHD events in relation to ALT was assessed in 1439 subjects participating in the Hoorn Study, using Cox survival analysis. Subjects with prevalent CVD/CHD and missing data were excluded. As compared with the first tertile, the age- and sex-adjusted hazard ratios (95% confidence intervals) for all-cause mortality, CVD events and CHD events were 1.30 (0.92–1.83), 1.40 (1.09–1.81) and 2.04 (1.35–3.10), respectively, for subjects in the upper tertile of ALT. After adjustment for components of the metabolic syndrome and traditional risk factors, the association of ALT and CHD events remained significant for subjects in the third relative to those in the first tertile, with a hazard ratio of 1.88 (1.21–2.92) and 1.75 (1.12–2.73), respectively. In conclusion, the predictive value of ALT for coronary events, seems independent of traditional risk factors and the features of the metabolic syndrome in a population-based cohort. Further studies should confirm these findings and elucidate the pathophysiological mechanisms.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gupte P.
        • Amarapurkar D.
        • Agal S.
        • et al.
        Non-alcoholic steatohepatitis in type 2 diabetes mellitus.
        J Gastroenterol Hepatol. 2004; 19: 854-858
        • Younossi Z.M.
        • Gramlich T.
        • Matteoni C.A.
        • et al.
        Nonalcoholic fatty liver disease in patients with type 2 diabetes.
        Clin Gastroenterol Hepatol. 2004; 2: 262-265
        • Cortez-Pinto H.
        • Camilo M.E.
        • Baptista A.
        • et al.
        Non-alcoholic fatty liver: another feature of the metabolic syndrome?.
        Clin Nutr. 1999; 18: 353-358
        • Knobler H.
        • Schattner A.
        • Zhornicki T.
        • et al.
        Fatty liver – an additional and treatable feature of the insulin resistance syndrome.
        QJM. 1999; 92: 73-79
        • Westerbacka J.
        • Corner A.
        • Tiikkainen M.
        • et al.
        Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk.
        Diabetologia. 2004; 47: 1360-1369
        • Sattar N.
        • Scherbakova O.
        • Ford I.
        • et al.
        Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.
        Diabetes. 2004; 53: 2855-2860
        • Vozarova B.
        • Stefan N.
        • Lindsay R.S.
        • et al.
        High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.
        Diabetes. 2002; 51: 1889-1895
        • Dekker J.M.
        • Girman C.
        • Rhodes T.
        • et al.
        Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.
        Circulation. 2005; 112: 666-673
        • Schindhelm R.K.
        • Diamant M.
        • Bakker S.J.L.
        • et al.
        Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus.
        Eur J Clin Invest. 2005; 35: 369-374
        • Brea A.
        • Mosquera D.
        • Martin E.
        • et al.
        Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study.
        Arterioscler Thromb Vasc Biol. 2005; 25: 1045-1050
        • Mooy J.M.
        • Grootenhuis P.A.
        • de Vries H.
        • et al.
        Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study.
        Diabetes Care. 1995; 18: 1270-1273
        • Bergmeyer H.U.
        • Horder M.
        • Rej R.
        International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (l-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2).
        J Clin Chem Clin Biochem. 1986; 24: 481-495
        • Kaplan M.M.
        Alanine aminotransferase levels: what's normal?.
        Ann Intern Med. 2002; 137: 49-51
        • Ratziu V.
        • Imbert-Bismut F.
        • Messous D.
        • Poynard T.
        The elusiveness of “normal” ALT in fatty liver.
        Hepatology. 2004; 39: 1172
        • Matthews D.R.
        • Hosker J.P.
        • Rudenski A.S.
        • et al.
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
        • Grootenhuis P.A.
        • Westenbrink S.
        • Sie C.M.
        • et al.
        A semiquantitative food frequency questionnaire for use in epidemiologic research among the elderly: validation by comparison with dietary history.
        J Clin Epidemiol. 1995; 48: 859-868
        • Kannel W.B.
        • Plehn J.F.
        • Cupples L.A.
        Cardiac failure and sudden death in the Framingham Study.
        Am Heart J. 1988; 115: 869-875
        • Arndt V.
        • Brenner H.
        • Rothenbacher D.
        • et al.
        Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality.
        Int Arch Occup Environ Health. 1998; 71: 405-412
        • Bruckert E.
        • Giral P.
        • Ratziu V.
        • et al.
        A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients.
        Metabolism. 2002; 51: 1071-1076
        • Targher G.
        • Bertolini L.
        • Padovani R.
        • et al.
        Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation.
        Diabetes Care. 2004; 27: 2498-2500
        • Hunt K.J.
        • Resendez R.G.
        • Williams K.
        • et al.
        National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study.
        Circulation. 2004; 110: 1251-1257
        • Kern P.A.
        • Ranganathan S.
        • Li C.
        • et al.
        Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.
        Am J Physiol Endocrinol Metab. 2001; 280: E745-E751
        • Kerner A.
        • Avizohar O.
        • Sella R.
        • et al.
        Association between elevated liver enzymes and C-reactive protein. possible hepatic contribution to systemic inflammation in the metabolic syndrome.
        Arterioscler Thromb Vasc Biol. 2004; : 01
        • Sakkinen P.
        • Abbott R.D.
        • Curb J.D.
        • et al.
        C-reactive protein and myocardial infarction.
        J Clin Epidemiol. 2002; 55: 445-451
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • et al.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        N Engl J Med. 2000; 342: 836-843
        • Unger R.H.
        Lipotoxic diseases.
        Annu Rev Med. 2002; 53: 319-336
        • Fishbein M.H.
        • Miner M.
        • Mogren C.
        • et al.
        The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis.
        J Pediatr Gastroenterol Nutr. 2003; 36: 54-61
        • Daniel S.
        • Ben Menachem T.
        • Vasudevan G.
        • et al.
        Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients.
        Am J Gastroenterol. 1999; 94: 3010-3014